Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
SLPI Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC-P, E |
|---|---|
| Primary Accession | P03973 |
| Other Accession | CAA28187, 758101 |
| Reactivity | Human, Mouse |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Calculated MW | Predicted: 15 kDa Observed: 19 kDa |
| Application Notes | SLPI antibody can be used for detection of SLPI by Western blot at 1 - 2 µg/mL. Antibody can also be used for immunohistochemistry starting at 10 µg/mL. |
| Gene ID | 6590 |
|---|---|
| Target/Specificity | SLPI; |
| Reconstitution & Storage | SLPI antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
| Precautions | SLPI Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | SLPI |
|---|---|
| Synonyms | WAP4, WFDC4 |
| Function | Acid-stable proteinase inhibitor with strong affinities for trypsin, chymotrypsin, elastase, and cathepsin G (PubMed:3533531, PubMed:3462719, PubMed:2039600, PubMed:2110563, PubMed:10702419, PubMed:24121345). Modulates the inflammatory and immune responses after bacterial infection, and after infection by the intracellular parasite L.major. Down-regulates responses to bacterial lipopolysaccharide (LPS) (By similarity). Plays a role in regulating the activation of NF-kappa- B and inflammatory responses (PubMed:10702419, PubMed:24352879). Has antimicrobial activity against mycobacteria, but not against salmonella. Contributes to normal resistance against infection by M.tuberculosis. Required for normal resistance to infection by L.major. Required for normal wound healing, probably by preventing tissue damage by limiting protease activity (By similarity). Together with ELANE, required for normal differentiation and proliferation of bone marrow myeloid cells (PubMed:24352879). |
| Cellular Location | Secreted |
| Tissue Location | Detected in blood plasma (PubMed:24352879). Detected in bone marrow myeloid cells (PubMed:24352879). Detected in airway sputum (PubMed:2039600). Detected in parotid gland secretions (PubMed:3462719). Detected in seminal plasma (at protein level) (PubMed:3485543). Detected in uterus cervix (PubMed:3533531) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
SLPI Antibody: Secretory leukocyte protease inhibitor (SLPI) is produced at mucosal surfaces, primarily the upper respiratory tract and is thought to play an important role in the antiprotease defense mechanism of the lung. SLPI forms inhibitory complexes with numerous proteolytic enzymes such as neutrophil elastase, and has been shown to possess anti-inflammatory, anti-viral, and antibacterial activities. Its expression in oral epithelial cells is stimulated by HIV-1 gp120, suggesting that SLPI is a component of the oral mucosal response to HIV-1. In peripheral blood monocytes, SLPI can inhibit NF-κB activation by inhibiting IκB degradation in the cytoplasm and competing for NF-κB binding sites in the nucleus. This attenuation of the inflammatory response may also act to suppress liver metastases and other cancer cell invasions, but promote blood-borne metastasis via an invasion-independent pathway.
References
Abe T, Kobayashi N, Yoshimura K, et al. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J. Clin. Invest. 1991; 87:2207-15.
Hiemstra PS, Fernie-King BA, McMichael J, et al. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapies. Curr. Pharm. Des. 2004; 10:2891-905.
Jana NK, Gray LR and Shugars DC. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SPLI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J. Virol. 2005; 79:6432-40.
Taggart CC, Cryan S-A, Weldon S, et al. Secretory leucoprotease inhibitor binds to NF-kB binding sites in monocytes and inhibits p65 binding. J. Exp. Med. 2005; 202:1659-68.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
